OOIR: Observatory of International Research

Papers

(The TQCC of Annals of the Rheumatic Diseases is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial	678
Response to: ‘Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study’ by Inamo	516
No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit	498
Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database	418
Response to: ‘Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues’ by Riddle and Perera	277
The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study	254
Response to: ‘Anti-Ku antibodies: important points to consider’ by Mahler et al	247
Response to: ‘Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ by N	245
Response to: ‘Questions on ‘Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population' by Guo et al' by Regueiro and Gonza	244
Vitamin K antagonist anticoagulant usage is associated with increased incidence and progression of osteoarthritis	241
Correspondence to ‘Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression‘	227
Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus	215
Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area	209
Response to: ‘Are patients with systemic lupus erythematosus at increased risk for COVID-19?‘ by Favalli et al	208
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update	207
Correction: Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study	202
Correspondence on ‘Long COVID: a new word for naming fibromyalgia?’ by Mariette	193
Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et al	191
Response to: ‘Correspondence on ‘Risk of venous thromboembolism in knee, hip and hand osteoarthritis: a general population-based cohort study’’ by Lin et al	184
Use of multidimensional composite scores in rheumatology: parsimony versus subtlety	183
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)	181
Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress s	175
Correspondence on ‘Standardisation of myositis-specific antibodies: where are we today?’	174
Potential for biosimilars in rheumatology in Africa	168
Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE	166

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON	166
COVID-19 and Behçet's disease: clinical case series	162
KLF2 enhancer variant rs4808485 increases lupus risk by modulating inflammasome machinery and cellular homoeostasis	158
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs	157
Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial	153
AB0655 RHEUMATOID ARTHRITIS ACTIVITY BEFORE AND AFTER COVID-19 LOCKDOWN PERIOD	152
POS1163 CHARACTERISTICS AND OUTCOMES IN A REAL-WORLD COHORT OF RHEUMATOID ARTHRITIS PATIENTS WITH COVID-19	145
AB0040 PYRUVATE DEHYDROGENASE KINASES AS A POTENTIAL TARGET IN THE TREATMENT OF OSTEOARTHRITIS TO UNLEASH THE METABOLIC FLOW?	140
AB0827 SERUM NESPHATIN-1 IN PATHOGENESIS RHEUMATOID ARTHRITIS	139
AB0357 LANDSCAPE REVIEW OF PATIENT-REPORTED OUTCOME MEASURES IN GIANT CELL ARTERITIS	137
AB0025 CITRULLINATED-PEPTIDE SPECIFIC CD4+ T CELL RESPONSES IN RHEUMATOID ARHRITIS	137
AB0485 DOES THE REASON OF DISCONTINUATION OF THE FIRST TNF INHIBITOR INFLUENCE THE RESPONSE TO THE SECOND TNF INHIBITOR IN SPONDYLOARTHRITIS? PILOT STUDY FROM THE MOROCCAN RBSMR REGISTRY	134
AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIE	133
OP0220 SECULAR TRENDS IN BASELINE CHARACTERISTICS, TREATMENT RETENTION AND RESPONSE RATES IN 17453 BIONAÏVE PSORIATIC ARTHRITIS PATIENTS INITIATING TNFI – RESULTS FROM THE EUROSPA COLLABORATION	133
POS1379 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER (FMF) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY	133
OP0131 ANIFROLUMAB EFFECTS ON RASH AND ARTHRITIS IN PATIENTS WITH SLE AND IMPACT OF INTERFERON SIGNAL IN POOLED DATA FROM PHASE 3 TRIALS	126
POS1273 A CHANGE IN A REHABILITATION MODEL INCREASES WORK CAPACITY AT 36 MONTHS IN LOW BACK PAIN	121
AB0030 BETA BOSWELLIC ACID BLOCKS INNATE IMMUNE RESPONSES IN MULTIPLE OA JOINT CELLS	120
POS0712 “EXTRA”- CRITERIA ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS (PRELIMINARY DATA)	117
POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY	116
POS1034 RESPONSE TO SEQUENTIAL LINES OF BIOLOGICAL THERAPY IN PSORIATIC ARTHRITIS: A SINGLE CENTRE COHORT STUDY	116
AB0138 A MOLECULAR SIGNATURE RESPONSE CLASSIFIER STRATIFIES SEROPOSITIVE RHEUMATOID ARTHRITIS PATIENTS BASED ON THEIR LIKELIHOOD OF INADEQUATE RESPONSE TO TNF INHIBITOR THERAPIES	111
AB0099 IN VIVO BONE MICROARCHITECTURE ANALYSIS IN A PSORIATIC ARTHRITIC PATIENT BEFORE AND AFTER ANTI-TNFΑ TREATMENT	109
AB0542 EVALUATION OF APREMILAST USE IN THE ROUTINE CLINICAL PRACTICE IN PATIENTS WITH PSORIATIC ARTHRITIS NAÏVE TO BIOLOGICAL TREATMENTS	107
AB0719 ASSOCIATION BETWEEN FIBROMYALGIA AND CHRONIC AUTOIMMUNE THYROIDITIS. RETROSPECTIVE OBSERVATIONAL DATA FROM A MONOCENTRIC ENDOCRINOLOGIST-RHEUMATOLOGIST COLLABORATIVE ANALYSIS	104
AB0397 EPIDEMIOLOGY AND CLINICAL FEATURES OF OPHTHALMOLOGICAL MANIFESTATIONS IN BEHÇET'S DISEASE. STUDY OF 50 PATIENTS OF A SERIES OF 120 PATIENTS IN A REGION IN NORTHERN SPAIN	103
AB0453 THE CHARACTERISTICS OF SSc-ILD PATIENTS WITH ACTIVE THERAPY IN DIFFERENT PROGNOSIS INTERVALS BASED ON DISCRIMINANT ANALYSIS	102
POS1430 EPIDEMIOLOGY OF LUPUS NEPHRITIS IN BRAZIL: FINDINGS FROM THE MACUNAÍMA STUDY - A NATIONWIDE MULTICENTRIC STUDY	100
POS1175 ASSESSMENT OF THE COVID-19 PANDEMIC FROM THE PERSPECTIVE OF PEOPLE WITH RHEUMATIC MUSCULOSKELETAL DISEASES IN EUROPE. RESULTS FROM THE REUMAVID STUDY (PHASE 1)	99
POS1086 DIFFERENCES IN PROINFLAMMATORY AND LIPID PROFILE BETWEEN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS	99
POS1019 INCONSISTENCY OF THE DEGREE OF CARDIOVASCULAR RISK WHEN ASSESSED USING DIFFERENT INDICES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS	97
AB0018 ACCUMULATION OF FUNCTIONALLY MATURE CD1C+ DENDRITIC CELLS CONTRIBUTES TO SYNOVIAL INFLAMMATION IN INFLAMMATORY ARTHRITIS	97
OP0257 VALUE OF COLOR DOPPLER ULTRASOUND ASSESSMENT OF SACROILIAC JOINTS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS:A COMPARISON WITH ANKYLOSING SPONDYLITIS	96
AB0338 PREGNANCY OUTCOMES IN ADOLESCENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	95
AB0183 T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA IN PATIENTS WITH FELTY'S SYNDROME	95
POS0606 DISEASE ACTIVITY AND PATIENTS-REPORTED OUTCOMES AFTER SWITCHING BETWEEN IL-6 RECEPTOR INHIBITORS AND JAK INHIBITORS: AN ANALYSIS FROM THE CORRONA REGISTRY	93
POS0784 AUDIOLOGIC EVALUATION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IMPACT OF HYDROXYCHLOROQUINE THERAPY	93
POS1305 TREATMENT RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS IN ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM THE NOR-DMARD STUDY	92
POS1288 TUBERCULOUS SPONDYLODISCITIS IN ELDERLY: EPIDEMIOLOGY, CLINICAL, FEATURES, TREATMENT AND OUTCOMES	88
AB0367 DIAGNOSTIC DELAY IN PATIENTS WITH GIANT CELL ARTERITIS	85
POS0461 RESPONSE TO BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS: RETHINKING OUR CLASSIFICATION	83
AB0230 OPTIMIZED TREATMENT OF BIOLOGICAL DISEASE MODIFYING DRUGS IN ROUTINE CLINICAL PRACTICE: SURVIVAL STUDY ANDANALYSIS OF PATIENT CHARACTERISTICS	83
POS0465 DIFFERENT CLINICAL RELEVANCE OF ANTI-CITRULLINATED PROTEINS ANTIBODIES IN RA PATIENTS	81
POS1141 ASSESSING RELEVANT JOINTS FOR MONITORING CPPD DISEASE: A SYSTEMATIC LITERATURE REVIEW OF IMAGING TECHNIQUES BY THE OMERACT ULTRASOUND – CPPD SUBGROUP	80
AB0050 A NOVEL METHOD FOR ISOLATION OF EXOSOMES FROM SYNOVIAL FLUID	80
POS1039 PSORIATIC ARTHRITIS AND PHYSICAL ACTIVITY, A SYSTEMATIC REVIEW	78
POS0703 CARDIAC ADVERSE EFFECTS OF LONG-TERM USE OF HYDROXYCHLOROQUINE IN SYSTEMIC LUPUS ERYTHEMATOSUS. SINGLE UNIVERSITY CENTER STUDY OF 109 PATIENTS	77
AB0853 IGG4-RELATED DISEASE CAUSING OCULAR NERVE PALSIES AND ORBITAL APEX SYNDROME: CASE REPORT AND LITERATURE REVIEW	77
POS1395 ASSESSMENT OF MICROVASCULAR INVOLVEMENT IN LUPUS NEPHRITIS PATIENTS BY RETINAL OCT-ANGIOGRAPHY AND KIDNEY BIOPSIES	77
POS0743 GENE EXPRESSION MICROARRAY IN LUPUS NEPHRITIS BY BIOINFORMATIC ANALYSIS	77

POS1166 UNDERSTANDING PRESCRIPTION BEHAVIOR ACROSS HEALTHCARE PROFESSIONALS IN TREATING KNEE OSTEOARTHRITIS BEFORE AND DURING THE 2020 COVID-19 PANDEMIC	76
POS1117 AGREEMENT BETWEEN VERTEBRAL FRACTURE ASSESSMENT AND RADIOGRAPHIC SCANS FOR THE DIAGNOSIS OF VERTEBRAL FRACTURE	76
AB0863-HPR FUNCTIONAL STATUS ASSESSMENT THROUGH SELF-REPORTED QUESTIONNAIRES IN RHEUMATIC DISEASES	76
AB0460 THE UTILITY OF USB CAPILLAROSCOPE FOR ASSESSMENT OF RAYNAUD'S PHENOMENON PATIENTS	76
AB0244 INFLUENCE OF BIOLOGICAL DRUGS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS	75
POS1438 EARLY FACTORS ASSOCIATED WITH THE INITIATION OF TREATMENT WITH BIOLOGICS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS – RESULTS FROM A SINGLE CENTRE RETROSPECTIVE COHORT STUDY	74
POS1208 EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE ARGENTINEAN SAR-COVID REGISTRY	74
POS0833 A RETROSPECTIVE COHORT STUDY IN CHINESE PATIENTS WITH ADULT POLYMYOSITIS AND DERMATOMYOSITIS: RISK OF COMORBIDITIES AND SUBCLASSIFICATION USING MACHINE LEARNING	73
AB0515 MICRONUTRIENT DEFICIENCIES IN PATIENTS WITH SPONDYLOARTHRITIS: AGE AND GENDER IMPLICATIONS	72
AB0155 COMPARATIVE ANALYSES OF SEROLOGICAL BIOMARKERS AND DISEASE CHARACTERISTICS BETWEEN ELDERLY ONSET RHEUMATOID ARTHRITIS (EORA) AND YOUNGER ONSET RHEUMATOID ARTHRITIS (YORA)	71
POS0992 PREVALENCE AND ASSOCIATED FACTORS OF SLEEP DISORDERS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. RESULTS FROM THE SPANISH ATLAS	70
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?	69
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al	69
Response to: ‘Presence of anti-phospholipid antibodies in COVID-19: a case series study’ by Amezcua-Guerra et al	68
Rare mimicker of sacroiliitis	68
Response to: ‘Correspondence on: irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Proft et al.	67
Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the G	67
Response to: â€˜Total adenosine deaminase highly correlated with adenosine deaminase 2 activity in serumâ€™ by Gao et al	67
Response to: ‘Reactive arthritis, a missing link: comment on the recent article from Sepriano et al' by Zeidler and Hudson	67
POS0760 HIGH LEVELS OF PROTEINS, CELL COUNTS, AND IL-6 IN CEREBROSPINAL FLUID IN PATIENTS WITH NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS ARE ASSOCIATED WITH DAMAGE ACCRUAL OF NON-NEUROPSYCHIATRIC	66
Response to: â€˜Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?â€™ by Teng et a	66
POS0775 COMBINED MODEL OF RENAL HISTOPATHOLOGY AND CLINICAL PARAMETERS BETTER PREDICT ONE YEAR RENAL OUTCOMES IN LUPUS NEPHRITIS: ANALYSIS OF 334 KIDNEY BIOPSIES	65
OP0089 RNAseq PROFILING OF RHEUMATOID ARTHRITIS PATIENTS TO PREDICT RESPONSE TO TOFACITINIB	65
POS0518 EFFECT OF FILGOTINIB (FIL) ON BODY WEIGHT (BW) AND BODY MASS INDEX (BMI) AND EFFECT OF BASELINE BMI ON THE EFFICACY AND SAFETY OF FIL IN RHEUMATOID ARTHRITIS (RA)	65
POS0481 DEFINING DISTINCT RESIDENT AND MIGRATORY FIBROBLAST POPULATIONS FROM SKIN BIOPSIES IN SYSTEMIC SCLEROSIS	64
POS0033 GENETIC INVESTIGATION OF TUMOUR NECROSIS FACTOR INHIBITOR IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS	64
POS1576-PARE IMPROVING METHOTREXATE PRESCRIBING AND DISPENSING SAFETY THROUGH A SIMPLE ADJUSTMENT TO ELECTRONIC PRESCRIBING.	64
POS0972 MOST DISEASE OUTCOME MEASURES BUT NOT ASDAS ARE INFLUENCED BY GENDER IN PATIENTS WITH AXIAL SpA: RESULTS FROM ASAS-PerSpA	64
AB0107 IMPACT OF SARS-CoV-2 INFECTION ON THE DISEASE ACTIVITY OF PATIENTS WITH PSORIATIC ARTHRITIS UNDER bDMARDs: REAL LIFE DATA	63
POS1036 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 2	63
POS0048-HPR HEALTHCARE PROFESSIONALS' EXPERIENCES OF LIFESTYLE MANAGEMENT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS – A QUALITATIVE STUDY	63
OP0128 ADHERENCE TO MEDICATIONS DURING PREGNANCY IN SYSTEMIC AUTOIMMUNE DISEASE	63
POS1011 THE STUDY OF DETECTION OF FECAL CALPROTECTIN AS A MARKER OF EARLY DIAGNOSIS OF THE DEVELOPMENT OF INFLAMMATORY BOWEL DISEASES IN PATIENTS WITH ANKYLOSING SPONDYLITIS	62
POS1451 DISCRIMINATORY CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED IN A TIGHT CONTROL SETTING VERSUS STANDARD OF CARE	62
POS1039 DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS: ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND ITS COMPONENTS	62
OP0240 ZOLEDRONATE-RELATED OSTEONECROSIS OF THE JAW IN OSTEOPOROSIS: INCIDENCE, RISK FACTORS AND COMPARISON TO ORAL BISPHOSPHONATES	61
POS1383 DIFFERENTIAL DIAGNOSTICS OF POLYMYALGIA RHEUMATICA IN A UNIVERSITY HOSPITAL IN FINLAND	61
POS0045-HPR HEALTHCARE PROFESSIONALS' ATTITUDE TOWARDS REMOTE MONITORING	60
OP0110 CELL-TYPE-SPECIFIC TRANSCRIPTOME ARCHITECTURE UNDERLYING THE ESTABLISHMENT AND EXACERBATION OF SYSTEMIC LUPUS ERYTHEMATOSUS	60
POS0018 REDUCTION OF DIFFUSE NOXIOUS INHIBITORY CONTROL IN ACTIVE INFLAMMATORY RHEUMATISM: A DEMONSTRATION OF CENTRAL SENSITISATION	60
POS1207 SEROCONVERSION AFTER A THIRD COVID-19 VACCINATION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH (ULTRA-)LOW DOSE RITUXIMAB WITH A PREVIOUS INSUFFICIENT HUMORAL RESPONSE IS DEPENDENT ON RITUXIM	60
POS1526-HPR WHICH FACTORS INFLUENCE PATIENTS' PREFERENCES FOR TELEHEALTH APPLICATIONS IN RHEUMATIC DISEASES? A QUALITATIVE STUDY	59
AB0031 DEEP IMMUNE PHENOTYPING OF SLE AND RA BY MACHINE LEARNING	59
POS0225 FLUIDIC SHEAR STRESS REDUCES TNFΑ-MEDIATED CARTILAGE DAMAGE IN A 3D MODEL OF DEGENERATIVE JOINT DISEASE	58
POS0740 IMPACT OF TIME TO REMISSION, FLARES AND EXPOSURE TO IMMUNOSUPPRESSIVES ON THE DEVELOPMENT OF ADVANCED CHRONIC KIDNEY DISEASE (STAGE IV OR WORSE) IN LUPUS NEPHRITIS	58
POS0883 BIOPHYSICAL PROPERTIES OF MONOCYTES INDICATE DISEASE ACTIVITY, SEVERITY OF FIBROTIC OR MICROVASCULAR MANIFESTATIONS AND THE RISK FOR PROGRESSION IN SYSTEMIC SCLEROSIS	57
POS1258 LESS THAN EXPECTED IMPACT OF RHEUMATOID ARTHRITIS AND AXIAL SPONDYLOARTHRITIS DISEASE ON COVID SEVERITY	57
POS0562 AUTOANTIBODIES TO JOINT PROTEINS AS NOVEL BIOMARKERS FOR THE DIAGNOSIS OF UNTREATED EARLY RHEUMATOID ARTHRITIS	56
Targeting the IL-6â€“Yapâ€“Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis	55
AB0428 TREATMENT PATTERNS OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN TAIWAN – A POPULATION-BASED ANALYSIS	55
POS0746 MEASUREMENT OF ANTI-SUPRABASIN ANTIBODIES, MULTIPLE CYTOKINES AND CHEMOKINES AS POTENTIAL PREDICTIVE BIOMARKERS FOR NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS	55
AB0290 COMPARATIVE FEATURES AND LONGITUDINAL BEHAVIOUR OF RHEUMATOID ARTHRITIS-ASSOCIATED UIP VERSUS IDIOPATHIC PULMONARY FIBROSIS: A SINGLE CENTRE COHORT STUDY	55
Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis	55
AB0999 Osteoarthritis. Pharmacoeconomics aspects of symptom-modifying therapy in real clinical practice.	55
AB1164 EFFICACY AND TOLERABILITY OF THE VACCINE AGAINST SARS- CoV-2 IN PATIENTS WITH SJOGREN'S SYNDROME RECEIVING VARIOUS TYPES OF THERAPY.	54
AB1389 COST-MINIMIZATION ANALYSIS IN RHEUMATOID ARTHRITIS IN SPAIN	54
AB0609 Gaps in the diagnosis of Takayasu Arteritis: a Romanian cohort	54
AB0842 Foot entheses ultrasound in spondyloarthritis: a case control study	53
AB0777 Influence of TNF inhibitors on subclinical atherosclerosis in Spondyloarthritis patients	53
AB1374 INTERSTITIAL LUNG DISEASE IN ASYMPTOMATIC PATIENTS AT THE ONSET OF INFLAMMATORY RHEUMATIC DISEASES	53
AB1134 BIBLIOMETRIC NETWORK ANALYSIS ON TOCILIZUMAB TREATMENT FOR COVID-19 PATIENTS	53
AB0427 RENAL INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: A DIFFICULT-TO-TREAT CLINICAL CASE	52
AB0345 THERAPEUTIC DRUG LEVELS TO ACHIEVE GOOD EULAR RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB: RESULTS FROM THE BIOLOGICS IN RHEUMATOID ARTHRITIS GENETICS AND GENOMICS STUDY	51
AB0563 ALEXITHYMIA IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	51
AB1349 CORRELATION OF CHRONIC INFLAMMATION MARKERS WITH ULTRASOUND SIGNS OF ATHEROSCLEROTIC HEART DISEASE AND BRACHIOCEPHALIC ARTERIES LESIONS IN RHEUMATOID ARTHRITIS	51
AB0267 FEATURES OF CARDIAC PATHOLOGY IN PATIENTS WITH SECONDARY OSTEOARTHRITIS ON THE BACKGROUND OF RHEUMATOID ARTHRITIS	51
AB0632 Intracardiac thrombosis and vascular involvement in Behçet's disease : two sides of the same coin ?	51
AB0761 Are we treating-to-target in spondyloarthritis (SpA)? A cross sectional analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry	50
AB1437 RHEUMATOLOGICAL IMMUNE-MEDIATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS BASED ON THE FDA ADVERSE EVENTS REPORTING SYSTEM	50
AB0285 MTX REDUCED THE CARDIOVASCULAR RISK IN RHEUMATIC DISEASES	50
AB1019 THE EFFECTS OF THREE DIFFERENT VITAMIN D3 SUPPLEMENTATION REGIMENS IN DEFICIENT SUBJECTS ON INFLAMMATORY CYTOKINES – A RANDOMISED OPEN-LABEL PARALLEL GROUPS STUDY	50
AB0640 PREVALENCE AND DETERMINANT FACTORS OF ENDOTHELIAL DYSFUNCTION IN ANCA ASSOCIATED VASCULITIS	50
AB0398 AURICULAR TRANSCUTANEOUS HI-FREQUENCY E-MMUNOTHERAPY SEQUENCES (ATHENS) FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: 1-YEAR CHANGES IN SYNOVITIS, OSTEITIS, AND BONE EROSION	50
AB1331 DIAGNOSTIC CAPABILITY OF ANESTHETIC INTRA-ARTICULAR INJECTIONS FOR FEMOROACETABULAR IMPINGEMENT	49
AB0878 Higher vitamin D serum level is associated with a better clinical response to bDMARDs in patients with axial spondyloarthritis.	49
AB0795 Are patients with ankylosing spondylitis afraid of falling compared to healthy controls?: the role of balance and posture	49
AB1448 DEEP VENOUS THROMBOSIS IN YOUNG ADULTS: INCIDENCE AND RISK FACTORS	49
AB1127 ANTIOSTEOPOROTIC TREATMENT AND COVID-19 RISK: IS THERE AN ASSOCIATION?	49
AB0928 CHARACTERISTICS OF AXIAL PSORIATIC ARTHRITIS PATIENTS WITH SYMMETRICAL AND ASYMMETRICAL SACROILIITIS	48
AB1207 RISK FACTORS FOR HIGHER RELAPSE RATE AND/OR PROLONGED GLUCOCORTICOID THERAPY IN POLYMYALGIA RHEUMATICA: MULTICENTRE STUDY IN 185 PATIENTS	48

AB0767 Comparison of the clinical-laboratory remission and the ASAS partial remission in patients with early axial spondyloarthritis	48
AB0642 Diagnosis of Cerebral vasculitis: retrospective study of 68 cases	48
AB1071 INFECTIONS IN RHEUMATOLOGIC PATIENTS IN A LATIN AMERICAN HOSPITAL, A 10-YEAR COHORT STUDY.	47
AB1351 FULL LONGITUDINAL NAILFOLD VIDEOCAPILLAROSCOPY ANALYSIS OF MICROVASCULAR CHANGES DURING NORMAL PREGNANCY	47
AB1123 EFFICACY AND SAFETY OF SARS-CoV-2 THIRD VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO DID NOT RESPOND AFTER PRIMARY TWO-DOSE REGIMEN	47
AB0882 Guselkumab: description of cardiovascular risk and efficacy in psoriasis and psoriatic arthritis in real clinical practice	46
AB1330 AUTOMATIC SUBPIXEL MEASUREMENT OF RADIOGRAPHIC FINGER JOINT SPACE NARROWING IN RHEUMATOID ARTHRITIS PATIENTS UNDER TOCILIZUMAB TREATMENT	46
AB0826 Keep an Eye on the Back: Spondyloarthritis in Patients with Acute Anterior Uveitis	45
AB1025 TRABECULAR BONE SCORE IN PATIENTS WITH AXIAL-SPONDYLOARTHRITIS	45
AB1419 PERFORMANCE OF AN EARLY TRIAGE SYSTEM FOR IDENTIFICATION OF PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES	45
AB0311 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS: FREQUENCY AND ASSOCIATED FACTORS	45
POS1337 ADULT-ONSET STILL'S DISEASE WITH ELDERLY ONSET, RESULTS FROM A MULTICENTRE STUDY AND ASSESSMENT OF AGE INFLUENCE ON CLINICAL FEATURES AND DISEASE OUTCOMES.	44
Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'	44
POS0360-PARE EDUCATIONAL NEEDS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND HEALTH PROFESSIONALS IN RHEUMATOLOGY: A SWISS CROSS-SECTIONAL QUALITATIVE ANALYSIS	44
POS0851 FREQUENCY OF METABOLIC SYNDROME AND ITS RELATIONSHIP WITH DISEASE CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS	44
POS1470-HPR KNOWING WHAT TO DO WITH THE DATA - A QUALITATIVE STUDY ON CHALLENGES OF USING SMARTPHONE-BASED ePROs IN RHEUMATOID ARTHRITIS	44
POS1566-PARE BEYOND MEDICATION – SELF MANAGEMENT AS A COMPLEMENTARY APPROACH FOR TREATING RMDS	44
POS1348 PATIENTS WITH VEXAS DIAGNOSED IN A DANISH TERTIARY RHEUMATOLOGY SETTING HAVE HIGHLY ELEVATED INFLAMMATORY MARKERS, MACROCYTIC ANEMIA, AND NEGATIVE AUTOIMMUNE BIOMARKERS.	44
OP0159 GENETICALLY DETERMINED CAUSAL RELATIONSHIP BETWEEN GOUT AND CARDIOVASCULAR DISEASE	43
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib	43
Genomic sequencing and functional analyses identify MAP4K3/GLK germline and somatic variants associated with systemic lupus erythematosus	43
POS0102 CALCIUM CONTAINING CRYSTALS ARE HIGHLY PREVALENT IN JOINT FLUID OF ADVANCED OSTEOARTHRITIS OF THE KNEE	43
Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study	43
Validation of the definition of rheumatoid arthritis flare based on SDAI and CDAI in clinical practice in two French independent cohorts	43
Response to: Where are the women ‘Heroes and Pillars of Rheumatology'?	43
OA susceptibility in mice is partially mediated by the gut microbiome, is transferrable via microbiome transplantation and is associated with immunophenotype changes	43
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells	42
COVID-19 in Italian patients with rheumatic autoimmune systemic diseases	42
News from EULAR	42
POS0796 SURVIVAL OF GIANT CELL ARTERITIS PATIENTS IN SLOVENIA	41
Response to: Correspondence on “Update on the diagnosis and management of systemic lupus erythematosus” by Zhou et al	41
AB0211 SWITCHING FROM ETANERCEPT ORIGINAL TO ETANERCEPT BIOSIMILAR: LONG TERM FOLLOW UP	41
Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients'	41
AB0334 THE FIRST 1000 DAYS OF LIFE AND REPRODUCTIVE DISORDERS IN WOMAN WITH RHEUMATIC DISEASE (RDS)	40
POS0715 QUANTIFYING THE PSYCHOSOCIAL IMPACT OF UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE (UCTD)	40
POS0847 IDENTIFICATION OF MOLECULAR PHENOTYPES IN SYSTEMIC SCLEROSIS BY INTEGRATIVE SYSTEMS ANALYSIS	40
AB0256 BARICITINIB (BARI) VERSUS BIOLOGICS IMPACT ON STEROID TAPERING IN RHEUMATOID ARTHRITIS (RA)	40
POS0939 WHEN DO THE ACTIVE SACROILIITIS MRI FINDINGS LOSS IN ANKYLOSING SPONDYLITIS? A RETROSPECTIVE, CROSS-SECTIONAL, OBSERVATIONAL STUDY	40
POS0807 RETINAL VESSEL CALIBERS AS A NON-INVASIVE BIOMARKER OF INFLAMMATORY BURDEN IN PRIMARY SYSTEMIC VASCULITIS	40
POS1193 CLINICAL FEATURES AND THE COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER	39
AB0109 VALIDATION OF SEPARATE PATIENT-REPORTED, CLINICAL AND LABORATORY FACTOR SCORES AS REPRESENTATION OF DISEASE BURDEN IN A POPULATION WITH ESTABLISHED RHEUMATOID ARTHRITIS	39
POS1173 A SHORT DELAY IN ARTHRITIS CARE IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY - LESSONS FROM THE CORONAVIRUS DISEASE 19 (COVID-19) PANDEMIC	39
POS0848 IDENTIFICATION OF POTENTIAL CRUCIAL GENES AND KEY PATHWAYS IN PULMONARY ARTERIAL HYPERTENSION WITH SYSTEMIC SCLEROSIS BY BIOINFORMATIC ANALYSIS	39
POS1416 THE IMPACT OF NON-PERSISTENCE ON RESOURCE UTILIZATION COSTS IN IMMUNE-MEDIATED RHEUMATIC DISEASES	39
POS1267 CLINICAL COURSE OF NEW SARS-COV-2 INFECTION IN CHILDREN WITH RHEUMATIC DISEASES: RETROSPECTIVE STUDY OF SINGLE PEDIATRIC RHEUMATOLOGY CENTER	39
AB0262 CLINICAL EFFICACY OF SWITCHING FROM ORAL TO SUBCUTANEOUS METHOTREXATE IN MANAGEMENT OF RHEUMATOID ARTHRITIS: EXPERIENCE FROM OUT-PATIENT SETTING OF A DISTRICT GENERAL HOSPITAL IN UK	38
AB0133 LATE-ONSET AND BONE LOSS IN RHEUMATOID ARTHRITIS: WHAT FACTORS SHOULD WE CONSIDER?	38
AB0346 RHUPUS SYNDROME: CLINICAL ANALYSIS OF 21 PATIENTS	38
AB0043 EFFECT OF ANTI-INFLAMMATORY MEDICATION ON INTERACTION OF SYNOVIAL FIBROBLASTS WITH MACROPHAGES IN RHEUMATOID ARTHRITIS	38
AB0014 METHOTREXATE - IMPLICATIONS OF PHARMACOGENETICS IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS	38
AB0160 HIGH NUMBER OF CONCOMITANT MEDICATIONS AND COMORBIDITIES AT BASELINE IN THE GLUCOCORTICOID LOW-DOSE OUTCOME IN RHEUMATOID ARTHRITIS (GLORIA) STUDY: AN OLDER POPULATION WITH RHEUMATOID ARTHRITIS	38
POS1139 COMPARISON OF THE FREQUENCY OF DETECTION OF EARLY SIGNS OF ATHEROSCLEROSIS IN PATIENTS WITH CALCIUM PYROPHOSPHATE CRYSTAL DEPOSITION DISEASE AND OSTEOARTHRITIS	37
POS1223 RAS GUANYL RELEASING PROTEIN 1 (RASGRP1) IN PERIPHERAL B CELLS LINKS RA TO COVID-19	37
POS1092 SUBCHONDRAL BONE NORMALIZATION AFTER KNEE JOINT DISTRACTION TREATMENT AS MEASURED WITH CT	37
POS1280 SPINAL LOCATION OF TUBERCULOSIS: WHAT HAS CHANGED OVER THE LAST YEARS?	37
POS1312 DRUG SURVIVAL FOR IL-6 INHIBITOR TOCILIZUMAB: DATA FROM A SINGLE-CENTER OBSERVATION	37
POS1320 DIFFERENCES IN CLINICAL MANIFESTATION AND DISEASE ACTIVITY OF PEDIATRIC BEHÇET DISEASE: A CROSS-SECTIONAL COHORT COMPARISON BETWEEN TURKEY AND UNITED STATES	37
POS0794 INCIDENCE AND PHENOTYPE OF ANTIPHOSPHOLIPID SYNDROME (APS) AFTER PREECLAMPSIA	37
AB0363 PERIOPERATIVE MANAGEMENT WITH BIOLOGICS ON SEVERE AORTIC VALVE REGURGITATION CAUSED BY BEHÇET'S SYNDROME: THE EXPERIENCE FROM A SINGLE CENTER	37
POS1329 A COHORT STUDY ON THE RISK OF DEVELOPING OBSTRUCTIVE SLEEP APNEA, TEMPOROMANDIBULAR JOINT DISORDERS AND CRANIOFACIAL DEFORMITIES IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS	37
AB0068 B- AND T- LYMPHOCYTE SUBSETS IN PATIENTS WITH EARLY AND PROGRESSED RHEUMATOID ARTHRITIS	36
POS1400 A SYSTEMATIC REVIEW OF INTERNATIONAL GUIDELINES REGARDING THE ROLE OF RADIOGRAPHY IN THE DIAGNOSIS OF OSTEOARTHRITIS	36
AB0117 CARDIOVASCULAR MORBIMORTALITY IN RHEUMATOID ARTHRITIS: A 5 YEAR FOLLOW-UP STUDY	36
AB0021 CHARACTERISATION OF AGE-ASSOCIATED B CELLS IN EARLY, DRUG NAÏVE RHEUMATOID ARTHRITIS	36
POS0791 DOSE-DEPENDENT RELATIONSHIP BETWEEN HISTORY OF DENTAL CARIES AND INCREASED RISK OF NEWLY-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: A NATIONWIDE POPULATION-BASED COHORT STUDY	36
POS1289 CHRONIC LOW BACK PAIN: THERAPEUTIC STRATEGIES AND CLINICAL OUTCOMES IN A MILITARY POPULATION	36
POS1225 INFLUENCE OF COLCHICINE PRESCRIPTION IN COVID19-RELATED HOSPITAL ADMISSIONS: A SURVIVAL ANALYSIS	36
POS1135 MONOSODIUM URATE CRYSTALS REDUCE SCHWANN CELLS VIABILITY	36
POS1436 EPIDEMIOLOGY OF LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH RHEUMATIC IMMUNE-MEDIATED DISEASES. SINGLE UNIVERSITY STUDY OF 1117 PATIENTS	35
AB0812 BIOMARKERS FOR CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE: A PILOT STUDY	35
AB0886-HPR ASSESSMENT OF SEASONAL VARIATIONS ON CHRONIC INFLAMMATORY RHEUMATISMS ACTIVITY	35
AB0467 EFFECTIVENESS OF GOLIMUMAB AFTER TNF-INHIBITOR FAILURE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOARTHRITIS: RESULTS AT 3 MONTHS FROM THE GO-BEYOND ITAL	35
POS1482-HPR PAIN CATASTROPHIZING IS ASSOCIATED WITH RESIDUAL PAIN AFTER REACHING IMPROVED CONDITIONS OF SWOLLEN/TENDER JOINTS AND SERUM C-REACTIVE PROTEIN LEVEL	35
POS1451 DEVELOPING A TOOL TO MEASURE THE LEARNING CURVE: ENTHESITIS ULTRASOUND IN PSORIASIS ARTHRITIS	35
POS1453 OVERLAPPING FEATURES OF RELAPSING POLYCHONDRITIS AND SWEET'S SYNDROME: COULD THIS BE VEXAS (VACUOLES, UBIQUITIN A1E MUTATION, X-LINKED, AUTOINFLAMMATORY, SOMATIC) SYNDROME?	34
AB0656 SARS-CoV-2 INFECTION IN PATIENTS WITH RHEUMATIC DISEASE: A TERTIARY SINGLE-CENTER EXPERIENCE	34
AB0724 CANDIDATE PREDICTIVE BIOMARKERS OF POOR TREATMENT RESPONSE IN OLIGOARTICULAR ONSET JUVENILE ARTHRITIS TO EARLY STEROID INJECTIONS	34
POS1293 RISK FACTORS OF NON-PROTECTIVE LEVELS OF ANTIBODIES TO VACCINES IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS	34
POS0878 ULTRASOUND ASSESSMENT OF DERMAL THICKNESS AND SKIN STIFFNESS IN UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE AT RISK FOR SYSTEMIC SCLEROSIS	34
AB0459 ARTICULAR INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS	34
AB0461 “SCLERODERMA-LIKE” PATTERN AS A PRESENTING FEATURE OF CONNECTIVE TISSUE DISEASES	34
AB0425 CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY	34
AB0883-HPR CHRONIC RHEUMATIC DISEASE MANAGEMENT AND THE SELF-EFFICACY OF RHEUMATOID ARTHRITIS	34
AB0434 VITAMIN D IN SYSTEMIC SCLEROSIS PATIENTS	34
AB0337 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS USING THE SLEQoL (SYSTEMIC LUPUS ERYTHEMATOSUS-SPECIFICQUALITY OF LIFE QUESTIONNAIRE)	33
POS1241 THE IMPACT OF THE COVID-19 PANDEMIC ON PHYSICAL FUNCTIONING AND MENTAL WELLBEING IN 824 PATIENTS WITH RHEUMATIC DISEASE OVER 8 MONTHS: PHYSICAL FUNCTIONING DECLINES	33
AB0189 LIPOPROTEIN ABNORMALITIES IN RHEUMATOID ARTHRITIS PATIENTS	33
POS1335 CLINICAL CHARACTERISTICS OF THE PULMONARY ARTERY INVOLVEMENT IN PATIENTS WITH BEHÇET'S SYNDROME: A SINGLE-CENTRE EXPERIENCE OF 61 PATIENTS	33
AB0252 EFFICACY OF A SECOND JANUS KINASE INHIBITOR THAT WAS SWITCHED FOR DIFFICULT-TO-TREAT RA IN CLINICAL PRACTICE	33
POS0736 IDENTIFICATION OF MOLECULAR PHENOTYPES AND IMMUNE CELL INFILTRATION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ACCORDING TO LONGITUDINAL GENE EXPRESSION	33
POS0714 WHITE MATTER HYPERINTENSITIES LEAD TO REDUCED PSYCHOMOTOR SPEED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND NEUROPSYCHIATRIC SYMPTOMS	33
POS1140 RISK FACTORS FOR THE DEVELOPMENT OF DIABETES MELLITUS IN PATIENTS WITH GOUT ACCORDING TO A 6-YEAR PROSPECTIVE FOLLOW-UP STUDY	32
AB0165 CENTRAL SENSITIZATION IN RHEUMATOID ARTHRITIS	32
AB0220 ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA) POSITIVITY IS ASSOCIATED WITH REDUCED WITHDRAWAL RATES OF ABATACEPT IN RHEUMATOID ARTHRITIS BUT ONLY IN PATIENTS WHO ARE ANTI-NUCLEAR ANTIBODY (ANA) N	32
POS1347 IMPACT OF CANAKINUMAB AND ANAKINRA ON PATIENT-REPORTED OUTCOMES IN ADULT-ONSET STILL'S DISEASE PATIENTS	32